The FDA approval of the ACTPen was supported by data from 2 studies: an open-label, randomized, 2-period, crossover Phase 1 study (N=188), and an open-label, non-randomized, observational Phase 4 ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved ACTPen, a single-dose prefilled autoinjector of tocilizumab, for the treatment of adult ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the subcutaneous formulation of Actemra for the treatment of polyarticular juvenile ...

March 25, 2013 (Tokyo) - Chugai Pharmaceutical Co., Ltd. [Head Office: Chuo-ku Tokyo; Chairman & CEO: Osamu Nagayama (hereafter, "Chugai")] announced today that the subcutaneous injection formulation ...

ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.

Actemra (tocilizumab) is a prescription drug that’s used to treat certain conditions that affect your immune system. Actemra can cause side effects that range from mild to serious. Examples include ...

The FDA has approved Actemra® (tocilizumab; Genentech) subcutaneous injection for slowing the rate of decline in pulmonary function in SSc-ILD. The Food and Drug Administration (FDA) has approved ...

GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...

Actemra (tocilizumab) has been given an emergency use authorization (EUA). This EUA allows for in-hospital use of Actemra as a treatment for COVID-19 in certain cases. You should not take any ...